

CODE/NAME & ADDRESS : C000138375 ACCESSION NO : **0061XC002081** AGE/SEX : 48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF23037661

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

DRAWN :

RECEIVED : 24/03/2024 11:19:09 REPORTED : 28/03/2024 15:15:16

Test Report Status Final Results Biological Reference Interval Units

<u></u>				
HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BEL	OW 40FEMALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	11.9 Low	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT	4.50	3.8 - 4.8	mil/μL	
WHITE BLOOD CELL (WBC) COUNT	7.04	4.0 - 10.0	thou/µL	
PLATELET COUNT	229	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	39.5	36 - 46	%	
MEAN CORPUSCULAR VOLUME (MCV)	87.8	83 - 101	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.4 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN	30.1 Low	31.5 - 34.5	g/dL	
CONCENTRATION (MCHC)	440 111 1		0/	
RED CELL DISTRIBUTION WIDTH (RDW)	14.2 High	11.6 - 14.0	%	
MENTZER INDEX	19.5			
MEAN PLATELET VOLUME (MPV)	10.9	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	69	40 - 80	%	
LYMPHOCYTES	23	20 - 40	%	
MONOCYTES	03	2 - 10	%	
EOSINOPHILS	05	1 - 6	%	

Interpretation(s)

BASOPHILS

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

< 1 - 2

00

Dr. Itisha Dhiman Pathologist Dr. Tarun Sharma Consultant Pathologist





Page 1 Of 17

View Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India

Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com



%



RECEIVED: 24/03/2024 11:19:09

PATIENT NAME: KAVIA SANTOSH REF. DOCTOR: DR. BOB

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL : KAVIF23037661 DRAWN

PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: DELHI

ABHA NO REPORTED :28/03/2024 15:15:16 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**





Page 2 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com





mm at 1 hr

REF. DOCTOR: DR. BOB PATIENT NAME: KAVIA SANTOSH

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Biological Reference Interval Final Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

10 0 - 20E.S.R

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.7 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5ADA Target: 7.0

Action suggested: > 8.0

ESTIMATED AVERAGE GLUCOSE(EAG) 116.9 High < 116.0 mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE:

. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**





Page 3 Of 17

PERFORMED AT:

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





REF. DOCTOR: DR. BOB PATIENT NAME: KAVIA SANTOSH

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL DRAWN

PATIENT ID : KAVIF23037661 F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED: 24/03/2024 11:19:09 DELHI ABHA NO REPORTED :28/03/2024 15:15:16 **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

8800465156

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test résults.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy, Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman

Pathologist

Dr. Tarun Sharma **Consultant Pathologist**



Page 4 Of 17





Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India

Tel: 0291-2646000, 2644000, Fax: CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com



PERFORMED AT:



CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE B **ABO GROUP**

METHOD: FORWARD/REVERSE

POSITIVE RH TYPE

METHOD: FORWARD/REVERSE

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 5 Of 17

PERFORMED AT:

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India Tel: 0291-2646000, 2644000, Fax: CIN - U74899PB1995PLC045956

Email: srl.jodhpur@gmail.com





CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0061XC002081

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID: ABHA NO

AGE/SEX

:48 Years Female

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Results Biological Reference Interval Units <u>Final</u>

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 88 Normal : < 100 mg/dL

Pre-diabetes: 100-125 Diabetes: >/=126

METHOD: SPECTROPHOTOMETRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 106 70 - 140 mg/dL

METHOD: SPECTROPHOTOMETRY

LIPID PROFILE WITH CALCULATED LDL, SERUM

CHOLESTEROL, TOTAL 130 < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High METHOD: SPECTROPHOTOMETRY

TRIGLYCERIDES 71 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: SPECTROPHOTOMETRY

METHOD: SPECTROPHOTOMETRY

51 mg/dL HDL CHOLESTEROL < 40 Low

>/=60 High

CHOLESTEROL LDL 65 < 100 Optimal mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High 160 - 189 High

>/= 190 Very High

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 6 Of 17







Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India



8800465156



PATIENT NAME: KAVIA SANTOSH REF. DOCTOR: DR. BOB CODE/NAME & ADDRESS : C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF23037661 DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 24/03/2024 11:19:09 DELHI REPORTED :28/03/2024 15:15:16 ABHA NO **NEW DELHI 110030**

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	79	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN	14.2	= 30.0 mg/dL</td
CHOL/HDL RATIO	2.5 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	1.3	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

A.CAD with > 1 feature of high risk group		
B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =	
50 mg/dl or polyvascular disease		
1. Established ASCVD 2. Diabetes with 2 m	najor risk factors or evidence of end organ damage 3.	
Familial Homozygous Hypercholesterolemia	ı	
1. Three major ASCVD risk factors. 2. Dia	betes with 1 major risk factor or no evidence of end organ	
damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
2 major ASCVD risk factors		
0-1 major ASCVD risk factors		
rosclerotic cardiovascular disease) Risk Fa	ctors	
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL		
	B. CAD with > 1 feature of Very high risk g 50 mg/dl or polyvascular disease 1. Established ASCVD 2. Diabetes with 2 n Familial Homozygous Hypercholesterolemia 1. Three major ASCVD risk factors. 2. Dia damage. 3. CKD stage 3B or 4. 4. LDL > 19 Artery Calcium - CAC > 300 AU. 7. Lipopre 2 major ASCVD risk factors 0-1 major ASCVD risk factors rosclerotic cardiovascular disease) Risk Fa in males and > or = 55 years in females	

Dr. Itisha Dhiman Pathologist Dr. Tarun Sharma Consultant Pathologist



Page 7 Of 17





PERFORMED AT:

Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India





CODE/NAME & ADDRESS : C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : KAVIF23037661

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 24/03/2024 11:19:09 DELHI

ABHA NO REPORTED :28/03/2024 15:15:16 **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	< OR = 30	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.30	0.2 - 1.0	mg/dL
METHOD: SPECTROPHOTOMETRY			
BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
METHOD: SPECTROPHOTOMETRY	0.00		
BILIRUBIN, INDIRECT	0.20	0.1 - 1.0	mg/dL
METHOD: SPECTROPHOTOMETRY			
TOTAL PROTEIN	6.9	6.4 - 8.2	g/dL
METHOD: SPECTROPHOTOMETRY	0.5	0.4.50	
ALBUMIN	3.5	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY	0.4		
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.0	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	15 - 37	U/L
METHOD: SPECTROPHOTOMETRY	40 111 1	24.0	117
ALANINE AMINOTRANSFERASE (ALT/SGPT)	40 High	< 34.0	U/L
METHOD: SPECTROPHOTOMETRY		00 400	117
ALKALINE PHOSPHATASE	115	30 - 120	U/L
METHOD : SPECTROPHOTOMETRY	0.6		
GAMMA GLUTAMYL TRANSFERASE (GGT)	36	5 - 55	U/L
METHOD: SPECTROPHOTOMETRY			
LACTATE DEHYDROGENASE	180	81 - 234	U/L
METHOD: SPECTROPHOTOMETRY			

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**





Page 8 Of 17





Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School

Jodhpur, 342001 Rajasthan, India

CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com





Female

PATIENT NAME: KAVIA SANTOSH REF. DOCTOR: DR. BOB

CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0061XC002081 PATIENT ID : KAVIF23037661

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :48 Years

RECEIVED : 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: SPECTROPHOTOMETRY	14	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD: SPECTROPHOTOMETRY	0.71	0.60 - 1.10	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD: SPECTROPHOTOMETRY	19.72 High	5.00 - 15.00	
URIC ACID, SERUM			
URIC ACID METHOD: SPECTROPHOTOMETRY	4.2	2.6 - 6.0	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY	6.9	6.4 - 8.2	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD: SPECTROPHOTOMETRY	3.5	3.4 - 5.0	g/dL
GLOBULIN			
GLOBULIN METHOD: CALCULATED PARAMETER	3.4	2.0 - 4.1	g/dL

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**





Page 9 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: KAVIF23037661

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

ELECTROLYTES (NA/K/CL), SERUM

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

SODIUM, SERUM	140	136 - 145	mmol/L
METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY			
POTASSIUM, SERUM	4.2	3.50 - 5.10	mmol/L
METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY			
CHLORIDE, SERUM	111	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 10 Of 17





Agilus Diagnostics Ltd.

M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





REF. DOCTOR: DR. BOB PATIENT NAME: KAVIA SANTOSH

CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

PATIENT ID : KAVIF23037661 DRAWN

CLIENT PATIENT ID: RECEIVED: 24/03/2024 11:19:09 ABHA NO REPORTED: 28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval** Units **Final**

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis,

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease,high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein,is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.
ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 11 Of 17

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001 Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

: KAVIF23037661

CLIENT PATIENT ID: ABHA NO

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
SPECIFIC GRAVITY	1.025	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	3-5	0-5	/HPF
EPITHELIAL CELLS	5-7	0-5	/HPF

NOT DETECTED **CASTS** NOT DETECTED **CRYSTALS**

DETECTED (+) BACTERIA NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma

Consultant Pathologist



Page 12 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : KAVIF23037661

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 24/03/2024 11:19:09

DELHI REPORTED :28/03/2024 15:15:16 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 13 Of 17







Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Tarun Sharma **Consultant Pathologist** Dr. Itisha Dhiman

Pathologist



Page 14 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001





REF. DOCTOR: DR. BOB PATIENT NAME: KAVIA SANTOSH

CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID: ABHA NO

RECEIVED: 24/03/2024 11:19:09

REPORTED :28/03/2024 15:15:16

Test Report Status Results **Biological Reference Interval** Units **Final**

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM			
ТЗ	131.80	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	
T4	7.18	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	μg/dL
TSH (ULTRASENSITIVE)	3.470	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000	,

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Total T4 FT4 Total T3 **Possible Conditions**

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**



Page 15 Of 17



Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





CODE/NAME & ADDRESS: C000138375 ACCESSION NO: 0061XC002081 AGE/SEX :48 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

: KAVIF23037661 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: DELHI

ABHA NO **NEW DELHI 110030** 8800465156

DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Test Report Status Final Results **Biological Reference Interval** Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist**





Page 16 Of 17







Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India





Female

REF. DOCTOR: DR. BOB PATIENT NAME: KAVIA SANTOSH

CODE/NAME & ADDRESS: C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

Final

DELHI

NEW DELHI 110030 8800465156

Test Report Status

ACCESSION NO: 0061XC002081

PATIENT ID : KAVIF23037661

CLIENT PATIENT ID: ABHA NO

Results

AGE/SEX :48 Years DRAWN

RECEIVED: 24/03/2024 11:19:09 REPORTED :28/03/2024 15:15:16

Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Itisha Dhiman **Pathologist**

Dr. Tarun Sharma **Consultant Pathologist** Page 17 Of 17











Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001

Rajasthan, India Tel: 0291-2646000, 2644000, Fax:

CIN - U74899PB1995PLC045956 Email: srl.jodhpur@gmail.com

